SARS-COV-2 screening in allogeneic hematopoietic stem cell donors: Implications for the evaluation process and eligibility.

Autor:	Crocchiolo R; ASST Grande Ospedale Metropolitano Niguarda, Milano, Italy. Electronic address: roberto.crocchiolo@ospedaleniguarda.it., Alfarano F; ASST Grande Ospedale Metropolitano Niguarda, Milano, Italy., Volpato E; ASST Grande Ospedale Metropolitano Niguarda, Milano, Italy., Pugliano M; ASST Grande Ospedale Metropolitano Niguarda, Milano, Italy., Cuppari I; ASST Grande Ospedale Metropolitano Niguarda, Milano, Italy., Mazza AM; ASST Grande Ospedale Metropolitano Niguarda, Milano, Italy., Bellio L; ASST Grande Ospedale Metropolitano Niguarda, Milano, Italy., Fanti D; ASST Grande Ospedale Metropolitano Niguarda, Milano, Italy., Vismara C; ASST Grande Ospedale Metropolitano Niguarda, Milano, Italy., Scaglione F; ASST Grande Ospedale Metropolitano Niguarda, Milano, Italy., Sacchi N; Italian Bone Marrow Donor Registry, Ospedale Galliera, Genova, Italy., Pollichieni S; Italian Bone Marrow Donor Registry, Ospedale Galliera, Genova, Italy., Mele L; HLA Laboratory, A.O. SS Antonio e Biagio e C. Arrigo, Alessandria, Italy., Diral E; ASST Grande Ospedale Metropolitano Niguarda, Milano, Italy., Grillo G; ASST Grande Ospedale Metropolitano Niguarda, Milano, Italy., Rossini S; ASST Grande Ospedale Metropolitano Niguarda, Milano, Italy.
Jazyk:	angličtina
Zdroj:	Hematology, transfusion and cell therapy [Hematol Transfus Cell Ther] 2022 Jan-Mar; Vol. 44 (1), pp. 13-16. Date of Electronic Publication: 2021 Dec 07.
DOI:	10.1016/j.htct.2021.09.017
Abstrakt:	Introduction: Soon after the onset of the SARS-CoV-2 pandemic, viral screening by nasopharyngeal swab became mandatory for allogeneic hematopoietic stem cell (HSC) donor eligibility. Methods: We described our monocenter experience with allogeneic HSC donors from February 1 to the October 31, 2020 to verify whether the introduction of SARS-CoV-2 screening altered the donor eligibility and/or entailed a prolongation of the evaluation process. Results: A total of 21 allogeneic HSC donors were screened during the above-mentioned period upon request by the local transplant physicians or by the Italian Bone Marrow Donor Registry; among the HSC donors ( n  = 17) who completed the eligibility process and further received the nasopharyngeal swab, all but one were negative for the presence of SARS-CoV-2. The positive donor remained asymptomatic for the whole duration of the infection, which lasted six weeks. However, he was temporarily excluded from donation. The median duration of the evaluation process was not significantly different, compared to the same period of 2019 ( p -value = 0.11). Conclusion: The mandatory SARS-CoV-2 screening in allogeneic HSC donors allowed for the detection of 6% positivity in this monocenter series over a 9-month period. Despite the inconvenience of this unexpected non-eligibility, the exclusion of a SARS-CoV-2 positive donor represented an important safety measure for the donor, with respect to a new and still partially unknown virus. The screening did not alter the length of the donor evaluation and thus, did not cause a delay in the eligibility process. Competing Interests: The authors declare no conflicts of interest. (© 2021 Associação Brasileira de Hematologia, Hemoterapia e Terapia Celular. Published by Elsevier España, S.L.U.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu